Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$55.61 USD

55.61
764,987

+0.09 (0.16%)

Updated May 15, 2024 04:00 PM ET

After-Market: $55.61 0.00 (0.00%) 6:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Catalent (CTLT) Q4 Earnings Expected to Decline

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medtronic (MDT) to Post Q1 Earnings: Will RTG Aid the Stock?

by Zacks Equity Research

Medtronic (MDT) is encouraged by robust and consistent constant currency growth in the RTG business over the last few quarters.

Medtronic (MDT) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Medtronic's (MDT) successful execution of growth policies should aid earnings results in the fiscal first quarter.

Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2019 results.

Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CTLT vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

CTLT vs. ZTS: Which Stock Is the Better Value Option?

Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Catalent (CTLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Catalent Acquires Gene Therapy Leader Paragon Bioservices

by Zacks Equity Research

Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.

Catalent (CTLT) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 8.89% and -4.14%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CTLT or ORINY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CTLT vs. ORINY: Which Stock Is the Better Value Option?

CTLT or NBIX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CTLT vs. NBIX: Which Stock Is the Better Value Option?

Champions Oncology (CSBR) Q3 Earnings: What's in Store?

by Zacks Equity Research

During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.

The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris

Nitish Marwah headshot

4 Drug Stocks to Buy Despite Price Hearing Woes

by Nitish Marwah

A burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.

Will Catalent Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Catalent.

CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CTLT vs. NBIX: Which Stock Is the Better Value Option?

Catalent (CTLT) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 21.62% and 3.11%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Catalent (CTLT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moving Average Crossover Alert: Catalent

by Zacks Equity Research

Catalent, Inc. (CTLT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Catalent (CTLT) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for September 19th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

    Catalent (CTLT) Q4 Earnings Top Estimates

    by Zacks Equity Research

    Catalent (CTLT) delivered earnings and revenue surprises of 9.84% and -0.11%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Will Medtronic (MDT) Q1 Earnings Show Overall Progress?

      by Zacks Equity Research

      In Q1, Medtronic (MDT) is expected to have sustained a steady market share across the core pacing, ICD and CRT product lines.

        Deere (DE) to Report Q3 Earnings: What's in the Offing?

        by Zacks Equity Research

        Deere's (DE) Q3 performance anticipated to be driven by Wirtgen acquisition and growing demand despite elevated expenses.